Physician profile
Emmanuel Barron
NPI 1598398034
$6,996.11
in general payments reported to CMS, 2019-2025
22 companies · $3,071 in 2025
The $3,071 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.77 · 2022: $195 · 2023: $1,354 · 2024: $2,352 · 2025: $3,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,738 · Travel and Lodging: $39.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,738.01 |
| Travel and Lodging | $39.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,578.52 | 2022-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $794.68 | 2022-2025 | Biktarvy |
| Novo Nordisk INC | $486.55 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $438.94 | 2023-2025 | Rexulti, Abilify Maintena |
| Novartis Pharmaceuticals Corporation | $305.50 | 2024-2025 | |
| Theratechnologies INC. | $217.19 | 2023-2025 | Trogarzo, Egrifta |
| Merck Sharp & Dohme LLC | $209.14 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $174.82 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $159.48 | 2021-2024 | Spravato, Symtuza |
| Napo Pharmaceuticals INC | $117.93 | 2023-2025 | Mytesi |
| Emd Serono, INC. | $96.35 | 2023-2024 | Serostim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.29 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $57.65 | 2025 | Zepbound, Mounjaro |
| Corcept Therapeutics | $57.03 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $51.91 | 2024 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37.98 | 2023 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $35.99 | 2024-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $25.58 | 2023 | Ingrezza |
| Exact Sciences Corporation | $23.11 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $23.08 | 2023 | Arexvy, Shingrix |
| Supernus Pharmaceuticals, INC. | $21.98 | 2024 | Qelbree |
| Hologic Sales and Service, LLC | $20.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Barron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.